Andrew A. Taylor
This is a likely match — the affiliation was inferred from OpenAlex, ORCID, and web sources but has not been fully confirmed. Treat with appropriate caution.
Role not yet determined Is this you? Add your title
Also affiliated: National Oceanic and Atmospheric Administration (2014); NOAA National Weather Service (2014); University of Oklahoma (2005)
Research Areas
Biomedical Subjects
Biography and Research Information
OverviewAI-generated summary
Andrew A. Taylor's research has focused on the evaluation of novel therapeutic agents. His work includes the pre-clinical assessment of NEOS-223, a peptidomimetic compound derived from (S)-valine-thiazole, for its potential as an anticancer agent and its activity as a P-glycoprotein inhibitor. Taylor has also published on topics related to speech acts and conversation, as well as historical and cultural analyses of Viking society and tattoos.
With an h-index of 3, Taylor has contributed to 13 publications, which have garnered 106 citations. His recent scholarly activity includes publications in 2022, indicating ongoing engagement in research.
Metrics
- h-index: 2
- Publications: 10
- Citations: 27
Selected Publications
-
Tattoos, “Tattoos,” Vikings, “Vikings,” and Vikings (2022)
Collaboration Network
Top Collaborators
- Abstract P39: Pre-clinical evaluation of NEOS-223, an (S)-valine-thiazole derived peptidomimetic N-heterocycle, as an anticancer agent and P-glycoprotein inhibitor
- Abstract P39: Pre-clinical evaluation of NEOS-223, an (S)-valine-thiazole derived peptidomimetic N-heterocycle, as an anticancer agent and P-glycoprotein inhibitor
- Abstract P39: Pre-clinical evaluation of NEOS-223, an (S)-valine-thiazole derived peptidomimetic N-heterocycle, as an anticancer agent and P-glycoprotein inhibitor
- Abstract P39: Pre-clinical evaluation of NEOS-223, an (S)-valine-thiazole derived peptidomimetic N-heterocycle, as an anticancer agent and P-glycoprotein inhibitor
- Abstract P39: Pre-clinical evaluation of NEOS-223, an (S)-valine-thiazole derived peptidomimetic N-heterocycle, as an anticancer agent and P-glycoprotein inhibitor
Similar Researchers
Based on overlapping research topics